Chronic kidney disease (CKD) is a persistent abnormality of kidney structure or function that has implications for health and is present for at least three months. It should not be defined by a single creatinine result or by estimated glomerular filtration rate (eGFR) alone. A person may have an eGFR in the normal or mildly reduced range and still have CKD because of persistent albuminuria, abnormal urine sediment, structural disease, or another marker of kidney damage. Conversely, a temporary reduction in kidney function during dehydration, infection, medication exposure, or acute illness does not automatically establish chronic disease. Current classification therefore combines the cause of CKD, the GFR category, and the level of albuminuria, often described as the CGA approach. This framework is more informative than the familiar five-stage description because two people with the same eGFR can have very different risks of progression and cardiovascular complications. Understanding the five GFR categories remains useful, but they should be interpreted together with albuminuria, underlying cause, rate of change, symptoms, comorbidities, and the patient’s overall clinical condition (KDIGO CKD Work Group S117–S314; NIDDK, “Identify and Evaluate”).
How Chronic Kidney Disease Is Diagnosed and Classified
The kidneys perform several essential functions: they filter waste products from blood, regulate water and electrolytes, contribute to acid–base balance, help control blood pressure, activate vitamin D, and produce erythropoietin for red-blood-cell formation. CKD can result when diseases injure glomeruli, tubules, interstitial tissue, blood vessels, or urinary drainage. Because remaining nephrons can compensate for lost function, early kidney disease frequently produces no obvious symptoms. Evaluation commonly includes serum creatinine with eGFR, a urine albumin-to-creatinine ratio (UACR), urinalysis, blood-pressure assessment, medication and medical history, and investigation of the likely cause. Imaging, serologic testing, genetic evaluation, or kidney biopsy may be appropriate in selected patients. Abnormal findings generally need evidence of persistence for at least three months unless previous medical records already establish chronicity. eGFR is an estimate rather than a direct measurement of kidney “efficiency,” and interpretation can be affected by factors such as unusual muscle mass or rapidly changing kidney function, which is why clinicians interpret the result alongside other evidence (KDIGO CKD Work Group S117–S314; NIDDK, “Identify and Evaluate”).
Albuminuria adds important prognostic information because leakage of albumin into urine is a marker of kidney damage and is associated with greater kidney and cardiovascular risk. KDIGO classifies albuminuria as A1 when UACR is below 30 mg/g, A2 when it is 30–300 mg/g, and A3 when it is above 300 mg/g. Risk generally rises as albuminuria increases and eGFR falls. This means that GFR categories G1 and G2 do not by themselves establish CKD when no other marker of kidney damage is present. A patient with an eGFR of 95 and persistent A3 albuminuria may have clinically important kidney disease, while a person with an eGFR of 75 but no evidence of structural or biochemical kidney damage may not meet the definition of CKD. The combined approach prevents staging from becoming a simplistic countdown to dialysis and instead emphasizes the patient’s underlying disease, kidney-damage markers, cardiovascular risk, and trajectory over time (KDIGO CKD Work Group S117–S314; NIDDK, “Albuminuria”).
The Five GFR Categories and What They Mean
| GFR category | eGFR (mL/min/1.73 m²) | Description |
| G1 | 90 or higher | Normal or high filtration |
| G2 | 60–89 | Mildly decreased filtration |
| G3a | 45–59 | Mildly to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | Below 15 | Kidney failure category |
G1 and G2 describe preserved or mildly reduced filtration and require another persistent marker of kidney damage before the diagnosis of CKD is established. Many people in these categories have no symptoms, so management centers on identifying the cause, reducing kidney and cardiovascular risk, controlling blood pressure and diabetes where present, monitoring albuminuria, and avoiding unnecessary nephrotoxic exposure. G3 is divided into G3a and G3b because risk increases substantially as filtration declines. Some patients remain asymptomatic, while others begin to develop anemia, hypertension, medication accumulation, mineral and bone abnormalities, or disturbances of electrolytes and acid–base balance. Routine dialysis is not a treatment for G3 disease. Care instead focuses on slowing progression, adjusting medications when renal clearance matters, monitoring complications, and arranging nephrology involvement when the cause is uncertain, progression is rapid, albuminuria is severe, or predicted kidney-failure risk is high (KDIGO CKD Work Group S117–S314).
G4 represents severe reduction in kidney function but not complete loss of function. Symptoms such as fatigue, poor appetite, itching, swelling, nausea, sleep disturbance, and difficulty concentrating may occur, although symptom severity varies considerably. Because the probability of kidney failure is higher, patients in G4 often need closer nephrology follow-up and early education about future treatment options. G5 is defined by an eGFR below 15 mL/min/1.73 m² and is termed the kidney-failure category, but the category does not mean that every patient must begin dialysis immediately. Some people remain clinically stable for a period with medical management, while others develop complications that require kidney replacement therapy. The decision to initiate dialysis is based on the overall clinical picture, including symptoms, refractory fluid overload, dangerous electrolyte or acid–base disturbances, uremic complications, nutrition, and quality of life rather than on a single eGFR threshold alone (KDIGO CKD Work Group S117–S314; NIDDK, “Choosing a Treatment”).
Causes, Risk Factors, and Why Progression Differs
Diabetes and high blood pressure are among the most common causes of CKD in adults. Persistent hyperglycemia can damage glomerular structures and increase albumin leakage, while hypertension can both cause kidney injury and worsen as kidney function declines. Other important causes include glomerular diseases, polycystic kidney disease, lupus and other autoimmune disorders, congenital abnormalities, recurrent urinary obstruction, vascular disease, selected infections, and medication or toxin exposure. Older age, family history, cardiovascular disease, prior acute kidney injury, smoking, and social conditions that limit access to preventive care can increase risk. The cause matters because prognosis and treatment differ substantially. A slowly progressive inherited disorder, diabetic kidney disease with heavy albuminuria, and an immune-mediated glomerulonephritis may occupy the same GFR category while requiring different investigations and therapies. CKD classification is therefore most useful when it describes the disease rather than merely assigning a stage number (NIDDK, “Chronic Kidney Disease”; Webster et al. 1238–52).
Progression is also highly variable. Some patients lose kidney function relatively quickly, some decline gradually over many years, and others remain stable without reaching kidney failure. Trends in eGFR and UACR are therefore more informative than a single isolated value. Increasing albuminuria, falling eGFR, uncontrolled hypertension, diabetes, recurrent acute kidney injury, and certain underlying diseases can indicate greater risk. CKD is also a major cardiovascular risk condition, meaning that prevention of heart attack, stroke, and heart failure is part of kidney care rather than a separate issue. This is why management includes attention to blood pressure, diabetes, smoking, lipids when indicated, physical activity, weight, and heart disease as well as kidney-specific laboratory values. Patients should be reassured that a CKD diagnosis is not an automatic prediction of dialysis, while also understanding that regular follow-up is important because risk can change over time (KDIGO CKD Work Group S117–S314; NIDDK, “Monitor Progression”).
Evidence-Based Management Across CKD
Management is individualized according to cause, albuminuria, GFR, cardiovascular risk, comorbidities, and treatment tolerance. Blood-pressure control is a central strategy, and angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers are particularly important for many patients with albuminuria, with monitoring of potassium and kidney function after initiation or dose changes. Sodium–glucose cotransporter-2 inhibitors now have an important kidney-protective role in many patients with CKD, including selected people without diabetes, while other medications may be appropriate according to diabetes, heart failure, albuminuria, potassium, and cardiovascular status. Drug doses should be reviewed as filtration declines because some medicines or metabolites accumulate when renal clearance is reduced. Patients should also discuss over-the-counter medicines and supplements with clinicians, especially nonsteroidal anti-inflammatory drugs, which can worsen kidney injury in susceptible people. Treatment aims not only to delay kidney failure but also to reduce cardiovascular events, manage symptoms, and preserve function and quality of life (KDIGO CKD Work Group S117–S314).
Lifestyle and preventive care support, but do not replace, medical treatment. Sodium reduction may help blood pressure and fluid control, smoking cessation lowers cardiovascular risk, and regular physical activity is beneficial when clinically appropriate. Protein intake should be individualized because excessive intake can be undesirable in some CKD settings while severe unsupervised restriction may contribute to malnutrition. Drinking excessive water does not “flush out” chronic kidney disease and can be harmful for patients with impaired fluid handling. Monitoring may include eGFR, UACR, potassium, bicarbonate, hemoglobin, calcium, phosphate, parathyroid hormone, and other tests depending on disease stage and therapy. Nephrology referral becomes especially important when the cause is uncertain, kidney function declines rapidly, albuminuria is severe, hypertension remains difficult to control, electrolyte disturbances recur, hereditary disease is suspected, or the predicted risk of kidney failure justifies specialized planning (KDIGO CKD Work Group S117–S314; NIDDK, “Identify and Evaluate”).
Advanced CKD, Kidney Failure, and Treatment Planning
Advanced CKD should prompt early preparation rather than emergency decision-making. When progression toward kidney failure appears likely, patients benefit from learning about hemodialysis, peritoneal dialysis, kidney transplantation, and conservative kidney management before any one option becomes urgently necessary. Early planning allows time for vascular access when hemodialysis is chosen, evaluation for transplant when appropriate, education about home therapies, discussion of treatment burden, and involvement of family members or caregivers. Kidney transplantation can provide excellent outcomes for eligible patients and in some circumstances can occur before dialysis begins, but it is not automatically required or suitable for every person with G5 CKD. Dialysis is likewise not a cure for kidney failure and replaces only part of normal kidney function. Its initiation should be guided by symptoms and complications rather than by the assumption that every eGFR below 15 requires immediate treatment (NIDDK, “Prepare for Kidney Replacement Therapy”; NIDDK, “Choosing a Treatment”).
Conservative kidney management is also an active treatment pathway rather than the absence of care. For patients who decide not to pursue dialysis or transplantation, particularly when serious comorbid illness makes treatment burdens substantial, care can focus on symptom relief, medication management, anemia and fluid control, nutrition, advance care planning, psychosocial support, and quality of life. Shared decision-making is essential because patients differ in health status, goals, values, independence, family support, and tolerance for treatment burden. The purpose of early education is to give patients meaningful choices rather than to push everyone toward the same modality. Urgent medical assessment remains necessary when advanced CKD is accompanied by severe shortness of breath, confusion, chest pain, marked swelling, very low urine output, persistent vomiting, suspected acute kidney injury, or other signs of serious deterioration. Educational descriptions of CKD stages cannot substitute for individualized medical evaluation (NIDDK, “Choosing a Treatment”; NIDDK, “Hemodialysis”).
Monitoring, Cardiovascular Risk, and Acute Kidney Injury
People with CKD are vulnerable to acute kidney injury during infection, dehydration, surgery, urinary obstruction, severe illness, or exposure to certain medications and contrast agents. A sudden rise in creatinine should therefore not be assumed to represent ordinary stage progression. Identifying and treating an acute cause may allow substantial recovery and prevent permanent loss of kidney function. Regular monitoring also helps clinicians distinguish a stable chronic condition from a meaningful downward trend. Frequency of testing should reflect the patient’s GFR, albuminuria, underlying disease, prior trajectory, and treatment changes rather than a fixed schedule for everyone. Monitoring is most useful when results lead to action: adjusting medication doses, improving blood-pressure or diabetes treatment, evaluating complications, or accelerating nephrology and kidney-failure planning when risk increases (KDIGO CKD Work Group S117–S314; NIDDK, “Monitor Progression”).
CKD care should also remain strongly connected with cardiovascular prevention. Many patients with CKD face substantial risk of heart attack, stroke, heart failure, and cardiovascular death, sometimes before kidney failure develops. The combined GFR and albuminuria classification helps communicate this broader prognosis because worsening albuminuria and declining filtration are associated with both renal and cardiovascular outcomes. Effective care therefore treats the patient rather than the stage label. A person with stable G3a disease, minimal albuminuria, and controlled blood pressure may have a different risk profile from someone with the same eGFR but rapidly increasing A3 albuminuria and diabetes. Recognizing those differences is the central advantage of modern CKD classification and prevents the five stages from being interpreted as a simple, inevitable sequence toward dialysis (KDIGO CKD Work Group S117–S314).
Conclusion
The five GFR categories remain a useful way to describe chronic kidney disease, but they are only one part of modern assessment. CKD is defined by persistent abnormalities of kidney structure or function and should be classified according to cause, GFR, and albuminuria. G1 and G2 require another marker of kidney damage before they constitute CKD; G3 is divided into G3a and G3b; G4 represents severely decreased function; and G5 is the kidney-failure category. None of these labels should be interpreted in isolation. Albuminuria, underlying disease, cardiovascular risk, symptoms, rate of progression, and patient goals all influence prognosis and treatment. Dialysis is not routine in stage 3 and is not started solely because a patient enters G5. Timely diagnosis, blood-pressure and diabetes management, kidney-protective therapy, medication review, avoidance of preventable kidney injury, cardiovascular prevention, monitoring, and early shared planning for advanced disease can slow progression and improve outcomes. The goal of staging is therefore not to predict an inevitable path but to support increasingly precise and individualized care (KDIGO CKD Work Group S117–S314; NIDDK, “Chronic Kidney Disease”).
References
Kidney Disease: Improving Global Outcomes CKD Work Group. “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.” Kidney International, vol. 105, suppl. 4S, 2024, pp. S117–S314.
National Institute of Diabetes and Digestive and Kidney Diseases. “Albuminuria: Albumin in the Urine.” U.S. Department of Health and Human Services.
National Institute of Diabetes and Digestive and Kidney Diseases. “Choosing a Treatment for Kidney Failure.” U.S. Department of Health and Human Services.
National Institute of Diabetes and Digestive and Kidney Diseases. “Chronic Kidney Disease (CKD).” U.S. Department of Health and Human Services.
National Institute of Diabetes and Digestive and Kidney Diseases. “Identify & Evaluate Patients with Chronic Kidney Disease.” U.S. Department of Health and Human Services.
Webster, Angela C., et al. “Chronic Kidney Disease.” The Lancet, vol. 389, no. 10075, 2017, pp. 1238–1252.
Cite This Work
To export a reference to this article please select a referencing stye below:
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
